Invicta Medical Completes $25M Series A Financing

Invicta Medical, Inc., a private sleep health company, today announced the closing of a $25 million Series A equity financing from a world-class syndicate of healthcare investors. Forepont Capital led this financing, with participation from ShangBay Ventures, Supermoon Capital, Aphelion Capital, DNS Capital, GreatPoint Ventures, Eclipse Ventures, and Seraph Group, as well as undisclosed strategic investors. Funds will be utilized to advance the development of Invicta’s proprietary, best-in-class solution to treat the millions of people suffering from obstructive sleep apnea (OSA).

“We are fortunate to work with this highly experienced investor group with demonstrated investment success in early-stage sleep, and neuromodulation therapy companies. This financing will enable us to bring our novel OSA therapy to market quickly,” said Rick O’Connor, President and CEO of Invicta Medical.

Obstructive sleep apnea happens when the soft tissues in the throat temporarily collapse, causing partial or complete airway blockage during sleep. It is estimated that 425 million people, globally, have moderate to severe OSA requiring treatment. Current therapy options have left most patients undertreated, tired, and at risk of severe health complications.

“As a longstanding academic, sleep physician, and someone who has dealt with many sleep therapies, I am excited by the potential impact that Invicta Medical’s therapy offers,” remarked Dr. Alan Schwartz, Adjunct Professor UPenn and medical advisor to Invicta Medical.

Dr. Ismail Kola, Chief Scientific Officer of Forepont Capital, stated, “Rick and his team at Invicta Medical have considerable experience introducing disruptive, world-class therapies to market. The Invicta Medical team and the platform they are developing is poised to disrupt sleep therapy much as they have done previously in other disease states at prior companies”

Founded in 2020 and headquartered in Santa Clara, California, Invicta Medical is a sleep therapy company revolutionizing the treatment for OSA. Privately held, the company is backed by Forepont Capital, ShangBay Capital, Supermoon Capital, DNS Capital, Aphelion Capital, GreatPoint Capital, Eclipse Ventures, Seraph Group, and undisclosed strategic investors.

Founded 2014 in New York, Forepont Capital Partners is a global asset manager in healthcare and life science.

Rick O’Connor, CEO, Invicta Medical